ABLI Stock Overview
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.13 |
| 52 Week High | SEK 0.34 |
| 52 Week Low | SEK 0.11 |
| Beta | 1.26 |
| 11 Month Change | -13.94% |
| 3 Month Change | -32.90% |
| 1 Year Change | -44.88% |
| 33 Year Change | -73.84% |
| 5 Year Change | -90.26% |
| Change since IPO | -97.95% |
Recent News & Updates
Recent updates
Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Oct 02
Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business
Dec 18Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation
Aug 24Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Aug 21We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate
Oct 13Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Mar 22How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?
Dec 06Shareholder Returns
| ABLI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -4.4% | -3.8% | -1.9% |
| 1Y | -44.9% | 17.8% | 12.5% |
Return vs Industry: ABLI underperformed the Swedish Biotechs industry which returned 17.3% over the past year.
Return vs Market: ABLI underperformed the Swedish Market which returned 12.3% over the past year.
Price Volatility
| ABLI volatility | |
|---|---|
| ABLI Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ABLI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ABLI's weekly volatility has decreased from 10% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Ellen Donnelly | abliva.com |
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children’s Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| ABLI fundamental statistics | |
|---|---|
| Market cap | SEK 215.03m |
| Earnings (TTM) | -SEK 102.12m |
| Revenue (TTM) | SEK 137.00k |
1,570x
P/S Ratio-2.1x
P/E RatioIs ABLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLI income statement (TTM) | |
|---|---|
| Revenue | SEK 137.00k |
| Cost of Revenue | SEK 72.82m |
| Gross Profit | -SEK 72.68m |
| Other Expenses | SEK 29.44m |
| Earnings | -SEK 102.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -0.063 |
| Gross Margin | -53,051.09% |
| Net Profit Margin | -74,542.34% |
| Debt/Equity Ratio | 0% |
How did ABLI perform over the long term?
See historical performance and comparison